Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $321498.0.

  • Lyell Immunopharma's Treasury Shares fell 9274.15% to $321498.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $321498.0, marking a year-over-year decrease of 9274.15%. This contributed to the annual value of $281190.0 for FY2024, which is 8643.47% down from last year.
  • Lyell Immunopharma's Treasury Shares amounted to $321498.0 in Q3 2025, which was down 9274.15% from $381671.0 recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Treasury Shares peaked at $9.1 million during Q1 2025, and registered a low of $281190.0 during Q4 2024.
  • Its 5-year average for Treasury Shares is $2.8 million, with a median of $2.6 million in 2021.
  • In the last 5 years, Lyell Immunopharma's Treasury Shares soared by 32391.74% in 2021 and then crashed by 9274.15% in 2025.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Treasury Shares stood at $2.6 million in 2021, then plummeted by 66.46% to $872077.0 in 2022, then surged by 137.69% to $2.1 million in 2023, then plummeted by 86.43% to $281190.0 in 2024, then rose by 14.33% to $321498.0 in 2025.
  • Its last three reported values are $321498.0 in Q3 2025, $381671.0 for Q2 2025, and $9.1 million during Q1 2025.